Key result
Higher admission procalcitonin predicts up to ~15% 30-day mortality in medical ED patients.
Why the study?
The prognostic value of admission procalcitonin levels in unselected emergency department patients remains undefined.
Do admission procalcitonin levels predict 30-day mortality in unselected adult medical emergency department patients?
Observational (n=6,970)
Yes
Do admission procalcitonin levels predict 30-day mortality in unselected adult medical emergency department patients?
Effect estimate: AUC 0.75
Admission procalcitonin is a strong, independent predictor of 30-day mortality across different medical diagnoses in unselected ED patients, independent of underlying infection.
PCT may aid ED risk stratification across diagnoses; leaves open whether it should guide management or requires prospective validation.
BACKGROUND: Procalcitonin (PCT), an inflammatory blood biomarker, is well studied in infectious diseases. Its prognostic value in unselected emergency department (ED) patients remains yet undefined. Herein, we investigated association of admission PCT levels and mortality in a large, international-multicenter ED patient cohort. METHODS: We prospectively enrolled 6970 unselected, consecutive, adult, medical patients seeking ED care in three tertiary-care hospitals in Switzerland, France and the USA. We used multivariable logistic regression models to examine association of admission PCT levels (as a continuous predictor and across cut-offs) and 30-day mortality. We also investigated subgroup effects by main diagnosis, comorbidities and clinical features at presentation. RESULTS: During the 30-day follow-up, 328 (4.7%) participants died. Mortality increased stepwise within higher PCT cut-offs (0.05, 0.1, 0.25, 0.5 ng/mL) from 1%, 3%, 7%, 13% to 15%, respectively. This association was also confirmed in a fully-adjusted model including age, gender, main symptom, main diagnosis and vital parameters on admission. Receiver operating characteristic (ROC) curve analysis showed that PCT differentiated well between survivors and non-survivors in the overall cohort (area under ROC curve [AUC] 0.75) with best results for patient with metabolic (AUC: 0.85) and cardiovascular disease (AUC: 0.82). Addition of PCT also improved the prognostic accuracy of the quick sequential organ failure assessment (qSOFA) score from an AUC of from 0.61 to 0.76 (p<0.001). Results were similar for other secondary endpoints including intensive care unit (ICU) admission and hospital readmission. CONCLUSIONS: In this large and heterogenous medical ED patient cohort, admission PCT was a strong and independent outcome predictor for 30-day mortality across different medical diagnoses independent of underlying infection. PCT may help to improve risk stratification in unselected medical ED patients.
No takes yet. Share an insight, caveat, or question.
Sager et al. (2017) conducted an observational in Medical emergencies (n=6,970). Admission procalcitonin (PCT) levels vs. Lower PCT levels was evaluated on 30-day mortality (AUC 0.75). Admission procalcitonin levels strongly predicted 30-day mortality in unselected medical ED patients, with mortality increasing stepwise from 1% to 15% across higher PCT cut-offs (overall AUC 0.75).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: